Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague–Dawley Rats

Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment... Oncol Ther (2016) 4:117–128 DOI 10.1007/s40487-016-0022-2 ORIGINAL RESEARCH Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague–Dawley Rats . . . . Pei Wang Ying Peng Xiaolan Zhang Fei Fei . . . . Shuyao Wang Siqi Feng Jingqiu Huang Hongbo Wang Jiye Aa Guangji Wang Received: March 15, 2016 / Published online: June 6, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com Methods: The method was verified and ABSTRACT successfully applied to evaluate the Introduction: By means of liquid–liquid pharmacokinetics of ponatinib in extraction with ethyl acetate, a rapid, Sprague–Dawley rats. sensitive, and specific LC–MS/MS method was Results: Ponatinib showed dose-dependent developed and validated for assaying ponatinib exposure in the circulation system, and the and the internal standard, warfarin. absolute bioavailabilities of ponatinib were 43.95 ± 2.40%, 47.69 ± 5.08% and 55.02 ± Enhanced Content To view enhanced content for this article go to www.medengine.com/Redeem/ 2.50% after intragastric administration of 7.5, 53D4F060083D3591. 15.0 and 30.0 mg/kg ponatinib in rats, Electronic supplementary material The online respectively. After consecutive administration version of this article (doi:10.1007/s40487-016-0022-2) at 3.75 mg/kg for 7 days, there was distinct contains supplementary material, which is available to authorized http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague–Dawley Rats

Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/liquid-chromatography-mass-spectrometry-mass-spectrometry-analysis-and-s5GoMTvkQX
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0022-2
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:117–128 DOI 10.1007/s40487-016-0022-2 ORIGINAL RESEARCH Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague–Dawley Rats . . . . Pei Wang Ying Peng Xiaolan Zhang Fei Fei . . . . Shuyao Wang Siqi Feng Jingqiu Huang Hongbo Wang Jiye Aa Guangji Wang Received: March 15, 2016 / Published online: June 6, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com Methods: The method was verified and ABSTRACT successfully applied to evaluate the Introduction: By means of liquid–liquid pharmacokinetics of ponatinib in extraction with ethyl acetate, a rapid, Sprague–Dawley rats. sensitive, and specific LC–MS/MS method was Results: Ponatinib showed dose-dependent developed and validated for assaying ponatinib exposure in the circulation system, and the and the internal standard, warfarin. absolute bioavailabilities of ponatinib were 43.95 ± 2.40%, 47.69 ± 5.08% and 55.02 ± Enhanced Content To view enhanced content for this article go to www.medengine.com/Redeem/ 2.50% after intragastric administration of 7.5, 53D4F060083D3591. 15.0 and 30.0 mg/kg ponatinib in rats, Electronic supplementary material The online respectively. After consecutive administration version of this article (doi:10.1007/s40487-016-0022-2) at 3.75 mg/kg for 7 days, there was distinct contains supplementary material, which is available to authorized

Journal

Oncology and Therapy – Springer Journals

Published: Jun 6, 2016

References

  • Effects of food on the pharmacokinetics of ponatinib in healthy subjects
    Narasimhan, NI; Dorer, DJ; Niland, K; Haluska, F; Sonnichsen, D
  • NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia
    O’Brien, S; Berman, E; Borghaei, H; Deangelo, DJ; Devetten, MP; Devine, S
  • Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
    Druker, BJ; Tamura, S; Buchdunger, E; Ohno, S; Segal, GM; Fanning, S
  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    O’Brien, SG; Guilhot, F; Larson, RA; Gathmann, I; Baccarani, M; Cervantes, F
  • Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification
    Gorre, ME; Mohammed, M; Ellwood, K; Hsu, N; Paquette, R; Rao, PN
  • Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
    Talpaz, M; Shah, NP; Kantarjian, H; Donato, N; Nicoll, J; Paquette, R
  • In vitro activity of Bcr–Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
    O’Hare, T; Walters, DK; Stoffregen, EP; Jia, T; Manley, PW; Mestan, J
  • AP24534, a pan-BCR–ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
    O’Hare, T; Shakespeare, WC; Zhu, X; Eide, CA; Rivera, VM; Wang, F
  • Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR–ABL) kinase including the T315I gatekeeper mutant
    Huang, WS; Metcalf, CA; Sundaramoorthi, R; Wang, YH; Zou, D; Thomas, RM
  • The novel BCR–ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2
    Sen, R; Natarajan, K; Bhullar, J; Shukla, S; Fang, HB; Cai, L
  • Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects
    Narasimhan, NI; Dorer, DJ; Davis, J; Turner, CD; Sonnichsen, D
  • Effects of food on the pharmacokinetics of ponatinib in healthy subjects
    Narasimhan, NI; Dorer, DJ; Niland, K; Haluska, F; Sonnichsen, D
  • Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects
    Narasimhan, NI; Dorer, DJ; Niland, K; Haluska, F; Sonnichsen, D
  • Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor alpha1
    Redpath, NT; Xu, Y; Wilson, NJ; Fabri, LJ; Baca, M; Andrews, AE
  • Quantitative determination of diterpenoid alkaloid Fuziline by hydrophilic interaction liquid chromatography (HILIC)-electrospray ionization mass spectrometry and its application to pharmacokinetic study in rats
    Sun, J; Zhang, F; Peng, Y; Liu, J; Zhong, Y; Wang, G
  • The national randomised trial of hormone replacement therapy in women with a history of early stage breast cancer: an update
    Marsden, J; Sacks, N
  • Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice
    Kamath, AV; Yip, V; Gupta, P; Boswell, CA; Bumbaca, D; Haughney, P